{"id":2519,"date":"2015-02-12T10:23:55","date_gmt":"2015-02-12T15:23:55","guid":{"rendered":"http:\/\/blogviejo.sld.cu\/inorbib\/?p=2519"},"modified":"2015-02-12T10:23:55","modified_gmt":"2015-02-12T15:23:55","slug":"ovarian-suppression-and-breast-cancer","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/inorbib\/2015\/02\/12\/ovarian-suppression-and-breast-cancer\/","title":{"rendered":"Ovarian suppression and breast cancer"},"content":{"rendered":"<p>NEW<\/p>\n<p>The Lancet <span style=\"color: #ff0000\">Oncology<\/span> Volume 16, No. 2, e56, February <span style=\"color: #ff0000\">2015<\/span><\/p>\n<p>Ovarian suppression and breast cancer<\/p>\n<p>Talha Khan Burki  DOI: http:\/\/dx.doi.org\/10.1016\/S1470-2045(14)71192-1  Article Info \u2022<\/p>\n<p>Summary Adding ovarian suppression to adjuvant tamoxifen does not have a significant effect on disease-free survival for premenopausal women with hormone-receptor-positive breast cancer, according to the primary analysis of the phase 3 SOFT study. The patients had all had prior surgery and were randomly assigned to one of three groups: tamoxifen alone (n=1018); tamoxifen plus ovarian suppression, delivered by monthly injections, bilateral oophorectomy, or bilateral ovarian irradiation (n=1015); or exemestane plus ovarian suppression (n=1014).<\/p>\n<p>Adici\u00f3n de supresi\u00f3n ov\u00e1rica a tamoxifeno adyuvante no tiene un efecto significativo sobre la supervivencia libre de enfermedad en mujeres premenop\u00e1usicas con c\u00e1ncer de mama con receptores hormonales positivos, de acuerdo con el an\u00e1lisis primario de la fase 3 de estudio SUAVE. Todos los pacientes hab\u00edan tenido una cirug\u00eda previa y fueron asignados aleatoriamente a uno de tres grupos: el tamoxifeno solo (n = 1.018); tamoxifeno m\u00e1s supresi\u00f3n ov\u00e1rica, entregado por inyecciones mensuales, ooforectom\u00eda bilateral, o irradiaci\u00f3n ov\u00e1rica bilateral (n = 1.015); o exemestano, m\u00e1s supresi\u00f3n ov\u00e1rica (n = 1014).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>NEW The Lancet Oncology Volume 16, No. 2, e56, February 2015 Ovarian suppression and breast cancer Talha Khan Burki DOI: http:\/\/dx.doi.org\/10.1016\/S1470-2045(14)71192-1 Article Info \u2022 Summary Adding ovarian suppression to adjuvant tamoxifen does not have a significant effect on disease-free survival for premenopausal women with hormone-receptor-positive breast cancer, according to the primary analysis of the phase [&hellip;]<\/p>\n","protected":false},"author":176,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[8],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts\/2519"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/users\/176"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/comments?post=2519"}],"version-history":[{"count":0,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts\/2519\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/media?parent=2519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/categories?post=2519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/tags?post=2519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}